DayOne gains importance
DayOne, a BaselArea.swiss initiative, is creating a world-leading healthcare innovation hub based on the strengths of the Basel region. A further important partner has joined to help achieve this goal.
The Department of Biosystems (D-BSSE) in Basel, which is part of the Federal Institute of Technology in Zurich (ETH), has become the latest partner of DayOne, according to a statement. With the partnership, the department will help promote digital healthcare applications and create a world-leading center for precision medicine.
Its goals are in line with those of BaselArea.swiss, which operates the DayOne initiative. BaselArea.swiss has access to sector and technology experts, doctors and scientists, and is planning to exploit the know-how of around 2,000 healthcare innovators currently based in the Basel region.
The initiative DayOne has six core activities – among them supporting the existing network, launching pioneering projects and providing collaborative workspaces. Another aspect is helping companies from abroad to settle in the Basel region, which BaselArea.swiss specializes in. Furthermore the initiative announced news concerning the other two core activities.
On September 9, the next DayOne Conference will be held at the University of Applied Sciences and Arts Northwestern Switzerland (FHNW) in Muttenz in the canton of Basel-Landschaft. Entitled “Shaping the Future of Health”, the conference is expected to attract around 400 innovators, patients and experts. It will look at topics including digitalization and ethics, and will showcase innovations from the DayOne Accelerator and others.
The accelerator is the initiative’s sixth core activity. BaselArea.swiss and the partner organizations received more than 150 applications for the accelerator, twice as many as last year. The 16 companies considered for the first round of the accelerator can present their projects at the DayOne Conference. Four companies will then be selected for funding under the accelerator from January 2020.
Share this article
You might also be interested in
Moderna is opening a location in Basel and is advancing the production of the coronavirus vaccine from there. The Swiss government has just signed a supply contract with the US company for 4.5 million doses of the vaccine.Read More
The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.Read More
The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.Read More
The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.Read More
Two thirds of the value added attributable to the pharmaceutical industry as a whole in Switzerland is generated in the Basel Area, as revealed by an Interpharma report. However, the region also shines in an international comparison. Interpharma CEO René Buholzer regards it as “probably the most productive life sciences location in the world”.Read More
Resistell AG, based in Muttenz in the canton of Basel-Landschaft, has received a grant of up to 2.5 million euros and additional equity capital financing from a European fund with the aim of accelerating innovation. The company is developing the world’s fastest test against antibiotic resistance.Read More